Literature DB >> 19456219

Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.

Sharon E Johnatty1, Jonathan Beesley, Xiaoqing Chen, Amanda B Spurdle, Anna Defazio, Penelope M Webb, Ellen L Goode, David N Rider, Robert A Vierkant, Stephanie Anderson, Anna H Wu, Malcolm Pike, David Van Den Berg, Kirsten Moysich, Roberta Ness, Jennifer Doherty, Mary-Anne Rossing, Celeste Leigh Pearce, Georgia Chenevix-Trench.   

Abstract

Fibroblast growth factor (FGF)-2 (basic) is a potent angiogenic molecule involved in tumor progression, and is one of several growth factors with a central role in ovarian carcinogenesis. We hypothesized that common single nucleotide polymorphisms (SNPs) in the FGF2 gene may alter angiogenic potential and thereby susceptibility to ovarian cancer. We analyzed 25 FGF2 tgSNPs using five independent study populations from the United States and Australia. Analysis was restricted to non-Hispanic White women with serous ovarian carcinoma (1269 cases and 2829 controls). There were no statistically significant associations between any FGF2 SNPs and ovarian cancer risk. There were two nominally statistically significant associations between heterozygosity for two FGF2 SNPs (rs308379 and rs308447; p < .05) and serous ovarian cancer risk in the combined dataset, but rare homozygous estimates did not achieve statistical significance, nor were they consistent with the log additive model of inheritance. Overall genetic variation in FGF2 does not appear to play a role in susceptibility to ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19456219      PMCID: PMC2844121          DOI: 10.1375/twin.12.3.269

Source DB:  PubMed          Journal:  Twin Res Hum Genet        ISSN: 1832-4274            Impact factor:   1.587


  34 in total

Review 1.  Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions.

Authors:  J K Dow; R W deVere White
Journal:  Urology       Date:  2000-06       Impact factor: 2.649

Review 2.  The genetics of ovarian cancer.

Authors:  Paul D P Pharoah; Bruce A J Ponder
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2002-08       Impact factor: 5.237

Review 3.  Fibroblast growth factors, their receptors and signaling.

Authors:  C J Powers; S W McLeskey; A Wellstein
Journal:  Endocr Relat Cancer       Date:  2000-09       Impact factor: 5.678

4.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.

Authors:  Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson
Journal:  Am J Hum Genet       Date:  2003-12-15       Impact factor: 11.025

5.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

6.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.

Authors:  S Purcell; S S Cherny; P C Sham
Journal:  Bioinformatics       Date:  2003-01       Impact factor: 6.937

Review 7.  Molecular aspects of ovarian cancer.

Authors:  Robert M Wenham; Johnathan M Lancaster; Andrew Berchuck
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2002-08       Impact factor: 5.237

8.  Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study.

Authors:  Malcolm C Pike; Celeste L Pearce; Ruth Peters; Wendy Cozen; Peggy Wan; Anna H Wu
Journal:  Fertil Steril       Date:  2004-07       Impact factor: 7.329

Review 9.  Role of genetic polymorphisms in tumour angiogenesis.

Authors:  S P Balasubramanian; N J Brown; M W R Reed
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

10.  Snagger: a user-friendly program for incorporating additional information for tagSNP selection.

Authors:  Christopher K Edlund; Won H Lee; Dalin Li; David J Van Den Berg; David V Conti
Journal:  BMC Bioinformatics       Date:  2008-03-27       Impact factor: 3.169

View more
  4 in total

1.  Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome.

Authors:  Qing H Meng; Enping Xu; Michelle A T Hildebrandt; Dong Liang; Karen Lu; Yuanqing Ye; Elizabeth A Wagar; Xifeng Wu
Journal:  Clin Chem       Date:  2013-10-21       Impact factor: 8.327

2.  Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".

Authors:  Sharon E Johnatty; Jonathan Beesley; Xiaoqing Chen; Stuart Macgregor; David L Duffy; Amanda B Spurdle; Anna deFazio; Natalie Gava; Penelope M Webb; Mary Anne Rossing; Jennifer Anne Doherty; Marc T Goodman; Galina Lurie; Pamela J Thompson; Lynne R Wilkens; Roberta B Ness; Kirsten B Moysich; Jenny Chang-Claude; Shan Wang-Gohrke; Daniel W Cramer; Kathryn L Terry; Susan E Hankinson; Shelley S Tworoger; Montserrat Garcia-Closas; Hannah Yang; Jolanta Lissowska; Stephen J Chanock; Paul D Pharoah; Honglin Song; Alice S Whitemore; Celeste L Pearce; Daniel O Stram; Anna H Wu; Malcolm C Pike; Simon A Gayther; Susan J Ramus; Usha Menon; Aleksandra Gentry-Maharaj; Hoda Anton-Culver; Argyrios Ziogas; Estrid Hogdall; Susanne K Kjaer; Claus Hogdall; Andrew Berchuck; Joellen M Schildkraut; Edwin S Iversen; Patricia G Moorman; Catherine M Phelan; Thomas A Sellers; Julie M Cunningham; Robert A Vierkant; David N Rider; Ellen L Goode; Izhak Haviv; Georgia Chenevix-Trench
Journal:  PLoS Genet       Date:  2010-07-08       Impact factor: 5.917

3.  Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer.

Authors:  María Gaibar; Miguel Galán; Alicia Romero-Lorca; Beatriz Antón; Diego Malón; Amalia Moreno; Ana Fernández-Santander; Apolonia Novillo
Journal:  Int J Mol Sci       Date:  2021-01-30       Impact factor: 5.923

4.  BTN3A3 inhibits the proliferation, migration and invasion of ovarian cancer cells by regulating ERK1/2 phosphorylation.

Authors:  Sihan Chen; Zhangyun Li; Yanyan Wang; Shaohua Fan
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.